bimekizumab
ucb pharmaceuticals
[' psa', 'bimekizumab']
no new safety signals compared with previous studies, efficacy across joint and skin outcomes, bimekizumab looks to be a promising potential therapy for psa patients #acr2022 
The CSF is a free educational resource specialising in cytokine signalling and inflammatory disease, providing medical education to clinicians around the globe.